Loading
Arcadia Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Kawakami Mark, was filed 05 Feb 2025.
Insider Decl.
59
Thresholds
n/a
Buy Volume
€277,016
32 ops. · all time
Sell Volume
€1M
15 ops. · all time
Who traded when
BuySaleMark Kawakami1 buy
Since the insiders bought
- -63.0%Entry US$4.86 · Close at T+365 US$1.80
- +61.1%Entry US$2.70 · Close at T+365 US$4.35
- -33.2%Entry US$4.59 · Close at T+365 US$3.07
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.14
Analyst consensus
Income statement
RevenueUS$4.9M
Gross profitUS$1.8M36% margin
EBITDA-US$10M-205% margin
Net income-US$2.3M-234.5% margin
Valuation
P/Book0.5x
Beta0.55
Balance sheet & cash
Free Cash Flow-US$4.7M
Profitability & ownership
ROE-430.9%
ROA-34.8%
% insiders15.9%
% institutions18.7%
Last declaration on 5 February 2025
Declarations59 total
700 shares@ US$2.4956.0% of flowCommon StockSEC:0000950170-25-014814:0
Canonical exit: 4 May 2025 (T+90)
700 shares@ US$2.4925.4% of flowCommon StockSEC:0000950170-25-014802:0
Canonical exit: 4 May 2025 (T+90)
700 shares@ US$2.0620.0% of flowCommon StockSEC:0000950170-24-099335:0
Canonical exit: 30 Oct 2024 (T+90)
700 shares@ US$2.0644.0% of flowCommon StockSEC:0000950170-24-099338:0
Canonical exit: 30 Oct 2024 (T+90)
700 shares@ US$2.0619.9% of flowCommon StockSEC:0000950170-24-011271:0
Canonical exit: 1 May 2024 (T+90)
649 shares@ US$3.6732.5% of flowCommon StockSEC:0001209191-23-044889:0
Canonical exit: 2 Nov 2023 (T+90)
5,000 shares@ US$4.31100.0% of flowCommon stockSEC:0001209191-23-032996:0
Canonical exit: 28 Aug 2023 (T+90)
700 shares@ US$0.232.2% of flowCommon StockSEC:0001209191-23-006429:0
Canonical exit: 2 May 2023 (T+90)
700 shares@ US$0.70100.0% of flowCommon StockSEC:0001209191-22-044269:0
Canonical exit: 30 Oct 2022 (T+90)
585 shares@ US$3.16Common StockSEC:0001209191-21-005219:0
Canonical exit: 1 Nov 2020 (T+90)
700 shares@ US$3.16Common StockSEC:0001209191-21-005213:0
Canonical exit: 1 Nov 2020 (T+90)
700 shares@ US$3.16Common StockSEC:0001209191-21-005218:0
Canonical exit: 1 Nov 2020 (T+90)
700 shares@ US$1.7269.5% of flowCommon StockSEC:0001209191-20-006294:0
Canonical exit: 3 May 2020 (T+90)
700 shares@ US$1.72100.0% of flowCommon StockSEC:0001209191-20-006282:0
Canonical exit: 3 May 2020 (T+90)
700 shares@ US$1.72100.0% of flowCommon StockSEC:0001209191-20-006290:0
Canonical exit: 3 May 2020 (T+90)
900 shares@ US$5.95Common StockSEC:0001209191-19-061814:0
Canonical exit: 22 Mar 2020 (T+90)
1,000 shares@ US$4.52Common StockSEC:0001209191-19-057375:0
Canonical exit: 17 Feb 2020 (T+90)
5,000 shares@ US$4.25Common stockSEC:0001209191-19-057084:0
Canonical exit: 16 Feb 2020 (T+90)
1,000 shares@ US$4.08Common stockSEC:0001209191-19-056884:0
Canonical exit: 12 Feb 2020 (T+90)
2,000 shares@ US$5.25Common StockSEC:0001209191-19-050493:0
Canonical exit: 22 Dec 2019 (T+90)
5,000 shares@ US$5.88Common StockSEC:0001209191-19-049954:0
Canonical exit: 16 Dec 2019 (T+90)
5,000 shares@ US$6.49Common StockSEC:0001209191-19-049067:0
Canonical exit: 9 Dec 2019 (T+90)
10,000 shares@ US$6.49Common StockSEC:0001209191-19-049067:1
Canonical exit: 9 Dec 2019 (T+90)
1,200 shares@ US$6.48Common StockSEC:0001209191-19-049070:0
Canonical exit: 9 Dec 2019 (T+90)
1,000 shares@ US$6.49Common StockSEC:0001209191-19-049077:0
Canonical exit: 9 Dec 2019 (T+90)
25 of 59 declarations
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. shows many purchases, but very small ones: 32 purchases, only 11 of them with an amount, worth EUR 33,861 in total with a median of EUR 1,335, against 15 sales (8 with an amount) worth EUR 36,633. The largest purchase, EUR 20,078, is Stanley Jacot Jr.'s, CEO, on May 30, 2023; next come Eric J. Rey, a director, with EUR 3,353 on June 8, 2017, and Thomas J. Schaefer, CFO, with EUR 2,175 on August 4, 2023.
The largest sales date from 2016: Steven F. Brandwein, Interim Chief Financial Officer, with EUR 18,260 on June 13, then Eric J. Rey with EUR 8,123 and Vic C. Knauf, Chief Scientific Officer, with EUR 4,621, both on February 1. Matthew T. Plavan, CEO, signs 13 filings, all purchases; Vic C. Knauf has 10 of which 5 sales, Eric J. Rey 9.
Read moreShow less
The 57 filings, published from February 3, 2016 to February 5, 2025, are concentrated in 2016 (16) and 2019 (18), with a single filing in 2025. On August 3, 2020, 3 filers acted on the same day. Across the full history, 5 purchase filings are classed as clustered. This US food and beverage company, listed on Nasdaq, is valued at USD 335,362; insiders hold 15.9% of it. Across 11 purchases with a 90-day return, the stored median is -23.6% (past results on record, not a forecast).
